|1.||Engert, Andreas: 1 article (07/2007)|
|2.||Fischkoff, Steven: 1 article (07/2007)|
|3.||Lin, Thomas: 1 article (07/2007)|
|4.||Borchmann, Peter: 1 article (07/2007)|
|5.||Ansell, Stephen M: 1 article (07/2007)|
|6.||Horwitz, Steven M: 1 article (07/2007)|
|7.||Assad, Albert: 1 article (07/2007)|
|8.||Graziano, Robert: 1 article (07/2007)|
|9.||Khan, Khuda Dad: 1 article (07/2007)|
|10.||Keler, Tibor: 1 article (07/2007)|
07/01/2007 - "To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed. "
12/01/2005 - "Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. "
01/01/2007 - "Further clinical evaluation of antibodies has been based largely on our knowledge of antigen expression on the surface of lymphoma cells and has led to the development of antibodies against CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544 [inotuzumab ozogamicin]), CD80 (galiximab), CD52 (alemtuzumab), CD2 (MEDI-507 [siplizumab]), CD30 (SGN-30 and MDX-060 [iratumumab]), and CD40 (SGN-40). "
|2.||Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
|4.||Hodgkin Disease (Hodgkin's Disease)
|5.||CMC544 (Inotuzumab Ozogamicin)
|6.||hLL2 agent (epratuzumab)